uniQure’s Huntington’s Disease Trial Shows Promising Results

October 16, 2025 | Last month, uniQure announced promising results from their Phase I/II study of AMT-130, the company’s gene therapy to treat Huntington’s disease. A participant pool of 29 patients in the early stages of Huntington’s disease was categorized into two groups—low-dose and high-dose—and compared to a control group of 1,600 untreated Huntington’s patients at similar disease stages.  

Compared to the low-dose group, those in the high-dose group showcased more consistent favorable results in functional, motor, and…